Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | GPR4 | P46093 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19609091 | 0.84 | FKBP1A (0.50) | FKBP1ACYP4A11CYP4F2ALDH1A1RAB9A | |
| SCHEMBL28403717 | 0.81 | KCNJ1 (0.52) | CYP4A11OPRD1CYP4F2LOXL2KCNH2 | |
| SCHEMBL8934905 | 0.80 | ME2 (0.57) | FKBP1APOLBNPC1TDP1GPR4 | |
| SCHEMBL19609289 | 0.80 | ALDH1A1 (0.46) | FKBP1ACYP4A11CYP4F2ALDH1A1RAB9A | |
| SCHEMBL653012 | 0.79 | NPC1 (0.54) | FKBP1AALDH1A1POLBGPR183NPC1 | |
| SCHEMBL653041 | 0.79 | GFER (0.58) | FKBP1AOPRD1POLBGPR183NPC1 | |
| SCHEMBL16485192 | 0.78 | NPC1 (0.50) | OPRD1ALDH1A1RAB9ANPC1KMT2A | |
| SCHEMBL8660373 | 0.78 | SIGMAR1 (0.62) | OPRD1ALDH1A1GPR183TDP1 | |
| SCHEMBL1838692 | 0.78 | NPC1 (0.73) | FKBP1AALDH1A1POLBNPC1TDP1 | |
| SCHEMBL24648923 | 0.78 | FKBP1A (0.71) | FKBP1AOPRD1ALDH1A1POLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3455204-B1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20220281815-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC | 2022-09-08 | — | — | US | disclosed |
| US-11352322-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352322-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2022-06-07 | — | — | US | disclosed |
| CN-109153636-B | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | 朱比连特埃皮科尔有限责任公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20200308110-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC | 2020-10-01 | — | — | US | disclosed |
| US-20200308110-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC | 2020-10-01 | — | — | US | disclosed |
| EP-3455204-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Biosys Ltd. (IN) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017195216-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017195216-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308110-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | FKBP1A 157/4885CYP4A11 989/4885OPRD1 2145/4885 |
| US-11352322-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | FKBP1A 157/4885CYP4A11 989/4885OPRD1 2145/4885 |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | FKBP1A 154/4885CYP4A11 654/4885OPRD1 2062/4885 |
| US-20220281815-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | FKBP1A 154/4885CYP4A11 654/4885OPRD1 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.